Laddar...
BIBF 1120 (Nintedanib), a triple angiokinase inhibitor, induces hypoxia but not EMT and blocks progression of preclinical models of lung and pancreatic cancer
Signaling from other angiokinases may underlie resistance to vascular endothelial growth factor (VEGF)-directed therapy. We evaluated the anti-tumor and biological effects of BIBF 1120 (nintedanib), a tyrosine kinase inhibitor that targets VEGF receptor (VEGFR), platelet-derived growth factor recept...
Sparad:
| Huvudupphovsmän: | , , , |
|---|---|
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
2013
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3681897/ https://ncbi.nlm.nih.gov/pubmed/23729403 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-12-0995 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|